Ketogenic Diet in the Treatment of Epilepsy

Epilepsy is one of the most disabling neurological diseases. Despite proper pharmacotherapy and the availability of 2nd and 3rd generation antiepileptic drugs, deep brain stimulation, and surgery, up to 30-40% of epilepsy patients remain drug-resistant. Consequences of this phenomenon include not on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nutrients 2024-04, Vol.16 (9), p.1258
Hauptverfasser: Borowicz-Reutt, Kinga, Krawczyk, Marlena, Czernia, Julia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 9
container_start_page 1258
container_title Nutrients
container_volume 16
creator Borowicz-Reutt, Kinga
Krawczyk, Marlena
Czernia, Julia
description Epilepsy is one of the most disabling neurological diseases. Despite proper pharmacotherapy and the availability of 2nd and 3rd generation antiepileptic drugs, deep brain stimulation, and surgery, up to 30-40% of epilepsy patients remain drug-resistant. Consequences of this phenomenon include not only decreased a quality of life, and cognitive, behavioral, and personal disorders, but also an increased risk of death, i.e., in the mechanism of sudden unexpected death in epilepsy patients (SUDEP). The main goals of epilepsy treatment include three basic issues: achieving the best possible seizure control, avoiding the undesired effects of treatment, and maintaining/improving the quality of patients' lives. Therefore, numerous attempts are made to offer alternative treatments for drug-resistant seizures, an example of which is the ketogenic diet. It is a long-known but rarely used dietary therapy for intractable seizures. One of the reasons for this is the unpalatability of the classic ketogenic diet, which reduces patient compliance and adherence rates. However, its antiseizure effects are often considered to be worth the effort. Until recently, the diet was considered the last-resort treatment. Currently, it is believed that a ketogenic diet should be used much earlier in patients with well-defined indications. In correctly qualified patients, seizure activity may be reduced by over 90% or even abolished for long periods after the diet is stopped. A ketogenic diet can be used in all age groups, although most of the available literature addresses pediatric epilepsy. In this article, we focus on the mechanisms of action, effectiveness, and adverse effects of different variants of the ketogenic diet, including its classic version, a medium-chain triglyceride diet, a modified Atkins diet, and a low glycemic index treatment.
doi_str_mv 10.3390/nu16091258
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153612876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A793574417</galeid><sourcerecordid>A793574417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-e702a42eb85ae96094e85ef67c6de8b39c4dcbc5f5bc1219983b6bb69fe4e7843</originalsourceid><addsrcrecordid>eNqF0UtLw0AQAOBFFFtqL_4ACXgRJXXfj6PU-sCCl3oOyWZSU_Iymxz6793aWh8I7h52Dt8MMzsInRI8Yczg66onEhtChT5AQ4oVDaXk7PBbPEBj51Z4cxRWkh2jAdOKUYHFEF09QVcvocptcJtDF-RV0L1CsGgh7kqouqDOglmTF9C49Qk6yuLCwXj3jtDL3WwxfQjnz_eP05t5aDnBXQgK05hTSLSIwfjmOGgBmVRWpqATZixPbWJFJhJLKDFGs0QmiTQZcFCasxG62NZt2vqtB9dFZe4sFEVcQd27iBHBJKHaz_IvxYIZaYRmnp7_oqu6bys_yIcigkrP9moZFxDlVVZ3bWw3RaMbZZhQnBPl1eQP5W8KZW7rCjL_Yz8TLrcJtq2dayGLmjYv43YdERxt9hh97dHjs12nfVJCuqefW2PvA5mTHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3053152658</pqid></control><display><type>article</type><title>Ketogenic Diet in the Treatment of Epilepsy</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Borowicz-Reutt, Kinga ; Krawczyk, Marlena ; Czernia, Julia</creator><creatorcontrib>Borowicz-Reutt, Kinga ; Krawczyk, Marlena ; Czernia, Julia</creatorcontrib><description>Epilepsy is one of the most disabling neurological diseases. Despite proper pharmacotherapy and the availability of 2nd and 3rd generation antiepileptic drugs, deep brain stimulation, and surgery, up to 30-40% of epilepsy patients remain drug-resistant. Consequences of this phenomenon include not only decreased a quality of life, and cognitive, behavioral, and personal disorders, but also an increased risk of death, i.e., in the mechanism of sudden unexpected death in epilepsy patients (SUDEP). The main goals of epilepsy treatment include three basic issues: achieving the best possible seizure control, avoiding the undesired effects of treatment, and maintaining/improving the quality of patients' lives. Therefore, numerous attempts are made to offer alternative treatments for drug-resistant seizures, an example of which is the ketogenic diet. It is a long-known but rarely used dietary therapy for intractable seizures. One of the reasons for this is the unpalatability of the classic ketogenic diet, which reduces patient compliance and adherence rates. However, its antiseizure effects are often considered to be worth the effort. Until recently, the diet was considered the last-resort treatment. Currently, it is believed that a ketogenic diet should be used much earlier in patients with well-defined indications. In correctly qualified patients, seizure activity may be reduced by over 90% or even abolished for long periods after the diet is stopped. A ketogenic diet can be used in all age groups, although most of the available literature addresses pediatric epilepsy. In this article, we focus on the mechanisms of action, effectiveness, and adverse effects of different variants of the ketogenic diet, including its classic version, a medium-chain triglyceride diet, a modified Atkins diet, and a low glycemic index treatment.</description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu16091258</identifier><identifier>PMID: 38732505</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age groups ; Anticonvulsants - administration &amp; dosage ; Anticonvulsants - therapeutic use ; Atkins diet ; brain ; Carbohydrates ; Child ; cognition ; Compliance ; Convulsions &amp; seizures ; death ; Diet ; diet therapy ; Diet, Ketogenic - methods ; Drug resistance ; Drug Resistant Epilepsy - diet therapy ; drug therapy ; Epilepsy ; Epilepsy - diet therapy ; Fatty acids ; Glucose ; glycemic index ; Humans ; ketogenic diet ; Lipids ; medium chain triacylglycerols ; Metabolism ; Nervous system ; Patient compliance ; Proteins ; Quality of Life ; risk ; Seizures (Medicine) ; surgery ; Teenagers ; Treatment Outcome ; Triglycerides ; Tuberous sclerosis</subject><ispartof>Nutrients, 2024-04, Vol.16 (9), p.1258</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c410t-e702a42eb85ae96094e85ef67c6de8b39c4dcbc5f5bc1219983b6bb69fe4e7843</cites><orcidid>0000-0002-1574-1974 ; 0009-0002-4446-386X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38732505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Borowicz-Reutt, Kinga</creatorcontrib><creatorcontrib>Krawczyk, Marlena</creatorcontrib><creatorcontrib>Czernia, Julia</creatorcontrib><title>Ketogenic Diet in the Treatment of Epilepsy</title><title>Nutrients</title><addtitle>Nutrients</addtitle><description>Epilepsy is one of the most disabling neurological diseases. Despite proper pharmacotherapy and the availability of 2nd and 3rd generation antiepileptic drugs, deep brain stimulation, and surgery, up to 30-40% of epilepsy patients remain drug-resistant. Consequences of this phenomenon include not only decreased a quality of life, and cognitive, behavioral, and personal disorders, but also an increased risk of death, i.e., in the mechanism of sudden unexpected death in epilepsy patients (SUDEP). The main goals of epilepsy treatment include three basic issues: achieving the best possible seizure control, avoiding the undesired effects of treatment, and maintaining/improving the quality of patients' lives. Therefore, numerous attempts are made to offer alternative treatments for drug-resistant seizures, an example of which is the ketogenic diet. It is a long-known but rarely used dietary therapy for intractable seizures. One of the reasons for this is the unpalatability of the classic ketogenic diet, which reduces patient compliance and adherence rates. However, its antiseizure effects are often considered to be worth the effort. Until recently, the diet was considered the last-resort treatment. Currently, it is believed that a ketogenic diet should be used much earlier in patients with well-defined indications. In correctly qualified patients, seizure activity may be reduced by over 90% or even abolished for long periods after the diet is stopped. A ketogenic diet can be used in all age groups, although most of the available literature addresses pediatric epilepsy. In this article, we focus on the mechanisms of action, effectiveness, and adverse effects of different variants of the ketogenic diet, including its classic version, a medium-chain triglyceride diet, a modified Atkins diet, and a low glycemic index treatment.</description><subject>Age groups</subject><subject>Anticonvulsants - administration &amp; dosage</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Atkins diet</subject><subject>brain</subject><subject>Carbohydrates</subject><subject>Child</subject><subject>cognition</subject><subject>Compliance</subject><subject>Convulsions &amp; seizures</subject><subject>death</subject><subject>Diet</subject><subject>diet therapy</subject><subject>Diet, Ketogenic - methods</subject><subject>Drug resistance</subject><subject>Drug Resistant Epilepsy - diet therapy</subject><subject>drug therapy</subject><subject>Epilepsy</subject><subject>Epilepsy - diet therapy</subject><subject>Fatty acids</subject><subject>Glucose</subject><subject>glycemic index</subject><subject>Humans</subject><subject>ketogenic diet</subject><subject>Lipids</subject><subject>medium chain triacylglycerols</subject><subject>Metabolism</subject><subject>Nervous system</subject><subject>Patient compliance</subject><subject>Proteins</subject><subject>Quality of Life</subject><subject>risk</subject><subject>Seizures (Medicine)</subject><subject>surgery</subject><subject>Teenagers</subject><subject>Treatment Outcome</subject><subject>Triglycerides</subject><subject>Tuberous sclerosis</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0UtLw0AQAOBFFFtqL_4ACXgRJXXfj6PU-sCCl3oOyWZSU_Iymxz6793aWh8I7h52Dt8MMzsInRI8Yczg66onEhtChT5AQ4oVDaXk7PBbPEBj51Z4cxRWkh2jAdOKUYHFEF09QVcvocptcJtDF-RV0L1CsGgh7kqouqDOglmTF9C49Qk6yuLCwXj3jtDL3WwxfQjnz_eP05t5aDnBXQgK05hTSLSIwfjmOGgBmVRWpqATZixPbWJFJhJLKDFGs0QmiTQZcFCasxG62NZt2vqtB9dFZe4sFEVcQd27iBHBJKHaz_IvxYIZaYRmnp7_oqu6bys_yIcigkrP9moZFxDlVVZ3bWw3RaMbZZhQnBPl1eQP5W8KZW7rCjL_Yz8TLrcJtq2dayGLmjYv43YdERxt9hh97dHjs12nfVJCuqefW2PvA5mTHA</recordid><startdate>20240424</startdate><enddate>20240424</enddate><creator>Borowicz-Reutt, Kinga</creator><creator>Krawczyk, Marlena</creator><creator>Czernia, Julia</creator><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0002-1574-1974</orcidid><orcidid>https://orcid.org/0009-0002-4446-386X</orcidid></search><sort><creationdate>20240424</creationdate><title>Ketogenic Diet in the Treatment of Epilepsy</title><author>Borowicz-Reutt, Kinga ; Krawczyk, Marlena ; Czernia, Julia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-e702a42eb85ae96094e85ef67c6de8b39c4dcbc5f5bc1219983b6bb69fe4e7843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age groups</topic><topic>Anticonvulsants - administration &amp; dosage</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Atkins diet</topic><topic>brain</topic><topic>Carbohydrates</topic><topic>Child</topic><topic>cognition</topic><topic>Compliance</topic><topic>Convulsions &amp; seizures</topic><topic>death</topic><topic>Diet</topic><topic>diet therapy</topic><topic>Diet, Ketogenic - methods</topic><topic>Drug resistance</topic><topic>Drug Resistant Epilepsy - diet therapy</topic><topic>drug therapy</topic><topic>Epilepsy</topic><topic>Epilepsy - diet therapy</topic><topic>Fatty acids</topic><topic>Glucose</topic><topic>glycemic index</topic><topic>Humans</topic><topic>ketogenic diet</topic><topic>Lipids</topic><topic>medium chain triacylglycerols</topic><topic>Metabolism</topic><topic>Nervous system</topic><topic>Patient compliance</topic><topic>Proteins</topic><topic>Quality of Life</topic><topic>risk</topic><topic>Seizures (Medicine)</topic><topic>surgery</topic><topic>Teenagers</topic><topic>Treatment Outcome</topic><topic>Triglycerides</topic><topic>Tuberous sclerosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borowicz-Reutt, Kinga</creatorcontrib><creatorcontrib>Krawczyk, Marlena</creatorcontrib><creatorcontrib>Czernia, Julia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Physical Education Index</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borowicz-Reutt, Kinga</au><au>Krawczyk, Marlena</au><au>Czernia, Julia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ketogenic Diet in the Treatment of Epilepsy</atitle><jtitle>Nutrients</jtitle><addtitle>Nutrients</addtitle><date>2024-04-24</date><risdate>2024</risdate><volume>16</volume><issue>9</issue><spage>1258</spage><pages>1258-</pages><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract>Epilepsy is one of the most disabling neurological diseases. Despite proper pharmacotherapy and the availability of 2nd and 3rd generation antiepileptic drugs, deep brain stimulation, and surgery, up to 30-40% of epilepsy patients remain drug-resistant. Consequences of this phenomenon include not only decreased a quality of life, and cognitive, behavioral, and personal disorders, but also an increased risk of death, i.e., in the mechanism of sudden unexpected death in epilepsy patients (SUDEP). The main goals of epilepsy treatment include three basic issues: achieving the best possible seizure control, avoiding the undesired effects of treatment, and maintaining/improving the quality of patients' lives. Therefore, numerous attempts are made to offer alternative treatments for drug-resistant seizures, an example of which is the ketogenic diet. It is a long-known but rarely used dietary therapy for intractable seizures. One of the reasons for this is the unpalatability of the classic ketogenic diet, which reduces patient compliance and adherence rates. However, its antiseizure effects are often considered to be worth the effort. Until recently, the diet was considered the last-resort treatment. Currently, it is believed that a ketogenic diet should be used much earlier in patients with well-defined indications. In correctly qualified patients, seizure activity may be reduced by over 90% or even abolished for long periods after the diet is stopped. A ketogenic diet can be used in all age groups, although most of the available literature addresses pediatric epilepsy. In this article, we focus on the mechanisms of action, effectiveness, and adverse effects of different variants of the ketogenic diet, including its classic version, a medium-chain triglyceride diet, a modified Atkins diet, and a low glycemic index treatment.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38732505</pmid><doi>10.3390/nu16091258</doi><orcidid>https://orcid.org/0000-0002-1574-1974</orcidid><orcidid>https://orcid.org/0009-0002-4446-386X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6643
ispartof Nutrients, 2024-04, Vol.16 (9), p.1258
issn 2072-6643
2072-6643
language eng
recordid cdi_proquest_miscellaneous_3153612876
source MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
subjects Age groups
Anticonvulsants - administration & dosage
Anticonvulsants - therapeutic use
Atkins diet
brain
Carbohydrates
Child
cognition
Compliance
Convulsions & seizures
death
Diet
diet therapy
Diet, Ketogenic - methods
Drug resistance
Drug Resistant Epilepsy - diet therapy
drug therapy
Epilepsy
Epilepsy - diet therapy
Fatty acids
Glucose
glycemic index
Humans
ketogenic diet
Lipids
medium chain triacylglycerols
Metabolism
Nervous system
Patient compliance
Proteins
Quality of Life
risk
Seizures (Medicine)
surgery
Teenagers
Treatment Outcome
Triglycerides
Tuberous sclerosis
title Ketogenic Diet in the Treatment of Epilepsy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T11%3A33%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ketogenic%20Diet%20in%20the%20Treatment%20of%20Epilepsy&rft.jtitle=Nutrients&rft.au=Borowicz-Reutt,%20Kinga&rft.date=2024-04-24&rft.volume=16&rft.issue=9&rft.spage=1258&rft.pages=1258-&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu16091258&rft_dat=%3Cgale_proqu%3EA793574417%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3053152658&rft_id=info:pmid/38732505&rft_galeid=A793574417&rfr_iscdi=true